Safety and Immunogenicity Observations Pooled from Eight Clinical Trials of Recombinant Human Thrombin

Journal of the American College of Surgeons

Volumn 210, Issue 2, 2010, Pages 199-204

  Ballard, Jeffrey L ^a   Weaver, Fred A ^b   Singla, Neil K ^c   Chapman, William C ^d   Alexander, W Allan ^e  

^a Orange County Inc   (United States)

^b USC UNIVERSITY HOSPITAL   (United States)

^c HUNTINGTON MEMORIAL HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN SPONGE; RECOMBINANT HUMAN THROMBIN; THROMBIN; UNCLASSIFIED DRUG;

ANEMIA; APPLICATION SITE PAIN; ARTERIOVENOUS SHUNT; ARTERY BYPASS; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG SAFETY; FEVER; GRAFT FAILURE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HEPATITIS C; HUMAN; HYPERKALEMIA; IMMUNOGENICITY; INSOMNIA; LIVER RESECTION; LUNG EMBOLISM; NAUSEA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PRURITUS; RESPIRATORY FAILURE; SEROMA; SKIN GRAFT; SPINE SURGERY; VOMITING; WOUND DEHISCENCE;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; THROMBIN;

EID: 74749097855     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2009.09.042     Document Type: Article

References (28)

1. ZymoGenetics, Inc. Prescribing information: RECOTHROM (2009)
2. Meehan W.P., and Bolton M.G. Recombinant human thrombin: demonstration of efficacy in models of surgical bleeding. [abstract P54]. J Surg Res 121 (2004) 323
3. Chapman W.C., Lockstadt H., Singla N., et al. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost 4 (2006) 2083-2085
4. Greenhalgh D.G., Gamelli R.L., Collins J., et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res 30 (2009) 371-379
5. Chapman W.C., Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 205 (2007) 256-265
6. Weaver F.A., Lew W., Granke K., et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 47 (2008) 1266-1273
7. Singla N.K., Ballard J.L., Moneta G., et al. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg 1 (2009) 68-74
8. King Pharmaceuticals, Inc. Prescribing information: Thrombin-JMI (2007)
9. Heffernan J.K., Ponce R.A., Zuckerman L.A., et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol 47 (2007) 48-58
10. Anderson C.D., Bowman L.J., and Chapman W.C. Topical use of recombinant human thrombin for operative hemostasis. Expert Opin Biol Ther 9 (2009) 133-137
11. Kessler C.M., and Ortel T.L. Recent developments in topical thrombins. Thromb Haemost 102 (2009) 15-24
12. OMRIX Biopharmaceuticals Ltd, Ethicon, and Inc. (J&J Wound Management) Prescribing information: Evithrom (2007)
13. Dorion R.P., Hamati H.F., Landis B., et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 122 (1998) 887-894
14. Ortel T.L., Mercer M.C., Thames E.H., et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233 (2001) 88-96
15. Lawson J.H., Lynn K.A., Vanmatre R.M., et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 79 (2005) 1037-1038
16. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20 Suppl 6 (2005) vi3-vi9
17. Koren E., Zuckerman L.A., and Mire-Sluis A.R. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol 3 (2002) 349-360
18. Schellekens H., and Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251 Suppl 2 (2004) II4-II9
19. Kromminga A., and Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann NY Acad Sci 1050 (2005) 257-265
20. Purcell R.T., and Lockey R.F. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 18 (2008) 335-342
21. Koren E., Smith H.W., Shores E., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333 (2008) 1-9
22. International Conference on Harmonisation (ICH) E2A guideline on clinical safety data management, definitions and standards for expedited reporting. http://www.ich.org/cache/compo/276-254-1.html Accessed November 11, 2009
23. Ballantyne J.C., Loach A.B., and Carr D.B. Itching after epidural and spinal opiates. Pain 33 (1988) 149-160
24. Bendtzen K., Hansen M.B., Ross C., and Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 19 (1998) 209-211
25. Lutz H.U., Binder C.J., and Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 30 (2009) 43-51
26. Laricchia-Robbio L., Moscato S., Genua A., et al. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol 173 (1997) 219-226
27. Ross C., Hansen M.B., Schyberg T., and Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol 82 (1990) 57-62
28. Elkon K., and Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 4 (2008) 491-498